10106 Investors following Wockhardt. Share this News with them.
0
Like this story, share it with millions of investors on M3
Wockhardt opposes Roche patent on Pegasys
The country's first product patent, granted in the amended patent regime to Swiss pharmaceutical company Roche on its Hepatitis C drug Pegasys, has been opposed. Mumbai-based drug maker Wockhardt has opposed the product patent on Pegasys at the Indian Patent Office.
The country's first product patent, granted in the amended patent regime to Swiss pharmaceutical company Roche on its Hepatitis C drug Pegasys, has been opposed. Mumbai-based drug maker Wockhardt has opposed the product patent on Pegasys at the Indian Patent Office.
Wockhardt's opposition to the product patent on Pegasys could well be the country's first post-grant opposition, said a patent lawyer familiar with the development. Roche had received a product patent on Pegasys in March last year.
By filing a post-grant opposition, drug companies are not just protecting their turf, but also putting to test provisions provided in the Patent Amendment Act 2005.
Patent regime
The Roche's Managing Director in India, Dr G.L. Telang, told Business Line that the product patent on Pegasys belongs to Hoffmann-La Roche and the company would respond to the opposition.
Wockhardt's opposition to the product patent on Pegasys could well be the country's first post-grant opposition, said a patent lawyer familiar with the development. Roche had received a product patent on Pegasys in March last year. 
